The drug didnt fail as a Phase I trial it passed both Phase I and Phase II but failed at Phase III and this was for another indication not neuropathic pain - also I think their partner Sosei might have a little bit of an idea of what they are doing aswell
These people are world leaders in the field - have you seen the client base
